Loading...
XSHE
000566
Market cap1.49bUSD
Dec 05, Last price  
8.14CNY
1D
0.62%
1Q
37.73%
Jan 2017
-35.96%
Name

Hainan Haiyao Co Ltd

Chart & Performance

D1W1MN
XSHE:000566 chart
P/E
—
P/S
10.66
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.44%
Rev. gr., 5y
-16.53%
Revenues
991m
-33.00%
210,271,048213,587,764241,718,975386,651,529517,205,207613,189,625721,847,493951,387,5331,052,288,0301,384,750,9601,678,281,8341,543,980,3801,824,521,5942,471,770,2212,445,289,3062,200,313,9772,059,062,7611,779,052,1931,478,580,692990,701,458
Net income
-1.53b
21,744,54324,552,981042,731,70765,596,16734,338,628105,075,28777,252,79093,844,973162,784,442195,271,278164,628,97786,626,637119,569,2030002,377,0500-1,525,200,923
CFO
-18m
L
26,315,56330,514,00406,813,46578,837,76151,608,62457,776,3812,367,913181,805,14714,983,199141,599,9840526,479,214000108,223,441142,170,662103,548,849-17,552,031
Dividend
Aug 15, 20180.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Hainan Haiyao Co., Ltd. manufactures and sells pharmaceutical products and medical devices in China and internationally. The company develops intermediates, APIs, innovative chemical drugs, modern Chinese medicines, biological drugs, cellular immunity products, and high-end medical devices. It offers its products in various forms, such as pills, tablet granules, tincture fluid extracts, powders, syrups, soft capsule raw materials, powder injections, and health foods in various antibiotic series, gastrointestinal medication series, anti-tumor medicine series, cochlear implant series, etc.; and vitamin C for injection scurvy, idiopathic methemoglobinemia, etc. The company also provides internet medical treatment and medical services. Hainan Haiyao Co., Ltd. was founded in 1965 and is headquartered in Haikou, China.
URL
http://www.haiyao.com.cn/
IPO date
May 25, 1994
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT